Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Ruboxistaurin
Другие языки:

Ruboxistaurin

Подписчиков: 0, рейтинг: 0
Ruboxistaurin
Ruboxistaurin.svg
Ball-and-stick model of the ruboxistaurin molecule
Clinical data
ATC code
  • none
Legal status
Legal status
  • US: Not FDA approved
Identifiers
  • (9S)-9-[(Dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20-dione
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C28H28N4O3
Molar mass 468.557 g·mol−1
3D model (JSmol)
  • CN(C[C@]1([H])CCN2C=C(C(C(O)=NC3=O)=C3C(C4=CC=CC=C45)=CN5CCO1)C6=CC=CC=C62)C
  • InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1 checkY
  • Key:ZCBUQCWBWNUWSU-SFHVURJKSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.

In February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an approvable letter from the US FDA for ruboxistaurin, with a request for an additional clinical trial, which would take 5 years to complete. Lilly has not made any further request for approval and ruboxistaurin is not approved by the FDA for any medical use.

Mechanism of action

Ruboxistaurin is an inhibitor of protein kinase C-beta.

External links



Новое сообщение